Terms: = Liver cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Prognosis
241 results:
1. Assessment of the Clinical Value of Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma.
Chen X; Mohammed AF; Li C
Clin Appl Thromb Hemost; 2024; 30():10760296231221535. PubMed ID: 38591958
[TBL] [Abstract] [Full Text] [Related]
2. Isocitrate dehydrogenase 2 regulates the proliferation of triple-negative breast cancer through the ferroptosis pathway.
Zhang C; Zhou Y; Chen T; Bhushan S; Sun S; Zhang P; Yang Y
Sci Rep; 2024 Feb; 14(1):4732. PubMed ID: 38413708
[TBL] [Abstract] [Full Text] [Related]
3. [neuroendocrine Carcinoma of the Non-Ampullary Duodenum-A Case Report].
Tsukamoto T; Edagawa E; Togano S; Hori T; Tsujio G; Kunimoto T; Kaizaki R; Inoue T; Takatsuka S; Fukushima H
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1700-1702. PubMed ID: 38303178
[TBL] [Abstract] [Full Text] [Related]
4. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
5. TBACkp: her2 expression status classification network focusing on intrinsic subenvironmental characteristics of breast cancer liver metastases.
Yang K; Song J; Liu M; Xue L; Liu S; Yin X; Liu K
Comput Biol Med; 2024 Mar; 170():108002. PubMed ID: 38277921
[TBL] [Abstract] [Full Text] [Related]
6. TH-4000, a hypoxia-activated pan-HER inhibitor, shows excellent preclinical efficacy for the treatment of her2
Shao X; Yang D; Shan L; Yan X; Xu D; Li L; Sun Y; Yu Q; Zhou H; Ding Y; Tang J
Arch Toxicol; 2024 Mar; 98(3):865-881. PubMed ID: 38212449
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic nomograms for breast cancer with lung metastasis: a SEER-based population study.
Xie Y; Lei C; Ma Y; Li Y; Yang M; Zhang Y; Law KN; Wang N; Qu S
BMC Womens Health; 2024 Jan; 24(1):16. PubMed ID: 38172874
[TBL] [Abstract] [Full Text] [Related]
8. ER+/PR- phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in her2-negative inflammatory breast cancer.
Luo Y; Li Q; Fang J; Pan C; Zhang L; Xu X; Qian S; Zhao X; Hou L
Sci Rep; 2024 Jan; 14(1):197. PubMed ID: 38167641
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and her2-negative metastatic breast cancer.
Wang W; Lei W; Fang Z; Jiang R; Wang X
BMC Cancer; 2024 Jan; 24(1):1. PubMed ID: 38166784
[TBL] [Abstract] [Full Text] [Related]
10. Albumin-bilirubin score predicts trastuzumab resistance in her2-positive breast cancer.
Huang WJ; Yuan JR; Zhang L; Wang W; Miao SD; Wang X; Wang RT
Cancer Biomark; 2023; 38(4):425-432. PubMed ID: 37980647
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
[TBL] [Abstract] [Full Text] [Related]
12. Circulating Tumor Cells Prediction in Hormone Receptor Positive her2-Negative Advanced Breast cancer: A Retrospective Analysis of the MONARCH 2 Trial.
Gerratana L; Kocherginsky M; Davis AA; D'Amico P; Reduzzi C; Puglisi F; Cristofanilli M
Oncologist; 2024 Feb; 29(2):123-131. PubMed ID: 37935631
[TBL] [Abstract] [Full Text] [Related]
13. Advanced renal pelvis carcinoma patient with an erbb2 insertion mutation: a case report.
Shang P; Lou C; Yin L; Tao C; Dong Y; Yang G; Yuan Z
J Int Med Res; 2023 Nov; 51(11):3000605231204502. PubMed ID: 37917812
[TBL] [Abstract] [Full Text] [Related]
14. Immune checkpoint inhibitor-related molecular markers predict prognosis in extrahepatic cholangiocarcinoma.
Jin B; Wang Y; Zhang B; Xu H; Lu X; Sang X; Wang W; Mao Y; Chen P; Wang S; Qian Z; Wang Y; Du S
Cancer Med; 2023 Oct; 12(20):20470-20481. PubMed ID: 37814942
[TBL] [Abstract] [Full Text] [Related]
15. Roles of long noncoding RNA in triple-negative breast cancer.
Das PK; Siddika A; Rashel KM; Auwal A; Soha K; Rahman MA; Pillai S; Islam F
Cancer Med; 2023 Oct; 12(20):20365-20379. PubMed ID: 37795578
[TBL] [Abstract] [Full Text] [Related]
16. Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.
Gerratana L; Davis AA; Velimirovic M; Clifton K; Hensing WL; Shah AN; Dai CS; Reduzzi C; D'Amico P; Wehbe F; Medford A; Wander SA; Gradishar WJ; Behdad A; Puglisi F; Ma CX; Bardia A; Cristofanilli M
Breast Cancer Res; 2023 Oct; 25(1):112. PubMed ID: 37784176
[TBL] [Abstract] [Full Text] [Related]
17. Histologic heterogeneity predicts patient prognosis of her2-positive metastatic breast cancer: A retrospective study based on SEER database.
Wang Y; Liang Y; Ye F; Luo D; Jin Y; Li Y; Zhao W; Chen B; Wang L; Yang Q
Cancer Med; 2023 Sep; 12(18):18597-18610. PubMed ID: 37605516
[TBL] [Abstract] [Full Text] [Related]
18. Improved survival in patients with isolated liver metastasis at initial diagnosis with surgery at primary and metastatic sites: A population-based study in patients with breast cancer.
Chai Y; Chen Y; Liu J; He M; Jiang M; Xu B; Li Q
Thorac Cancer; 2023 Sep; 14(27):2793-2803. PubMed ID: 37558505
[TBL] [Abstract] [Full Text] [Related]
19. Inetetamab in combination with rapamycin and chemotherapy for trastuzumab-treated metastatic human epidermal growth factor receptor 2-positive breast cancer with abnormal activation of PI3K/Akt/mTOR pathway.
Wang A; Li C; Jiang Q; Jiang S
Cancer Rep (Hoboken); 2023 Sep; 6(9):e1864. PubMed ID: 37501598
[TBL] [Abstract] [Full Text] [Related]
20. [A Case of Breast Carcinoma That Changed Subtype to Squamous Cell Carcinoma after Chemotherapy].
Konishi K; Araya J; Nagabuchi M; Sakamoto T; Ogino J; Hirano S
Gan To Kagaku Ryoho; 2023 Jul; 50(7):825-827. PubMed ID: 37496230
[TBL] [Abstract] [Full Text] [Related]
[Next]
